These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Addolorato G; Caputo F; Capristo E; Domenicali M; Bernardi M; Janiri L; Agabio R; Colombo G; Gessa GL; Gasbarrini G Alcohol Alcohol; 2002; 37(5):504-8. PubMed ID: 12217947 [TBL] [Abstract][Full Text] [Related]
10. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009 [TBL] [Abstract][Full Text] [Related]
11. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Colombo G; Addolorato G; Agabio R; Carai MA; Pibiri F; Serra S; Vacca G; Gessa GL Neurotox Res; 2004; 6(5):403-14. PubMed ID: 15545024 [TBL] [Abstract][Full Text] [Related]
12. Tetrodotoxin alleviates acute heroin withdrawal syndrome: a multicentre, randomized, double-blind, placebo-controlled study. Song H; Li J; Lu CL; Kang L; Xie L; Zhang YY; Zhou XB; Zhong S Clin Exp Pharmacol Physiol; 2011 Aug; 38(8):510-4. PubMed ID: 21575032 [TBL] [Abstract][Full Text] [Related]
13. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. Beraha EM; Salemink E; Goudriaan AE; Bakker A; de Jong D; Smits N; Zwart JW; Geest DV; Bodewits P; Schiphof T; Defourny H; van Tricht M; van den Brink W; Wiers RW Eur Neuropsychopharmacol; 2016 Dec; 26(12):1950-1959. PubMed ID: 27842939 [TBL] [Abstract][Full Text] [Related]
15. Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial. Moosavyzadeh A; Mokri A; Ghaffari F; Faghihzadeh S; Azizi H; Jafari Hajati R; Naseri M J Altern Complement Med; 2020 May; 26(5):376-383. PubMed ID: 32109133 [No Abstract] [Full Text] [Related]
16. Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. Addolorato G; Caputo F; Capristo E; Colombo G; Gessa GL; Gasbarrini G Alcohol Clin Exp Res; 2000 Jan; 24(1):67-71. PubMed ID: 10656195 [TBL] [Abstract][Full Text] [Related]
17. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421 [TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961 [TBL] [Abstract][Full Text] [Related]
19. FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study. Paterson LM; Barker D; Cro S; Mozgunov P; Phillips R; Smith C; Nahar L; Paterson S; Lingford-Hughes AR Trials; 2022 Oct; 23(1):880. PubMed ID: 36258248 [TBL] [Abstract][Full Text] [Related]